Polycystic Ovary Syndrome (PCOS) affects approximately 10-15% of women of reproductive age worldwide and is a hallmark manifestation of neuroendocrine imbalance in functional medicine. The core pathophysiology of PCOS includes insulin resistance (present in about 70% of cases), hyperandrogenism, and ovulatory dysfunction, which create a vicious cycle.
Inositol is a class of cyclic sugar alcohols. Myo-inositol (MI) and D-chiro-inositol (DCI) play key roles in insulin signaling. MI promotes the membrane translocation of glucose transporter GLUT4, improving insulin sensitivity; DCI supports glycogen synthesis and the conversion of androgens to estrogens.
Key findings: The MI:DCI ratio varies across tissues. In the ovaries, it is approximately 100:1, whereas in muscle and liver, it is about 1.5:1. Patients with PCOS exhibit abnormally elevated DCI levels in follicular fluid, disrupting the MI:DCI balance. Supplementation with MI:DCI at a 40:1 ratio (mimicking physiological plasma levels) has demonstrated significant efficacy in multiple randomized controlled trials.
Research from the University of Catania, Italy, shows that daily supplementation with MI 2000mg + DCI 5 mg (ratio 40:1) for 6 months significantly improves insulin sensitivity in women with PCOS. Ovulation rates increased from 15% to 65%, and serum testosterone levels dropped by approximately 50%. These results are comparable to metformin but with fewer side effects.
Hong Kong Dynas Group Co., Ltd. offers an Inositol 40:1 formula (MI + DCI) in the NeuroEndocrine Balance Series, combined with DIM (to support healthy estrogen metabolism) and Vitex (to regulate luteinizing hormone), creating a comprehensive female endocrine regulation solution available in capsule and drop forms.
